Fundraising Fox
Cyteir Therapeutics
Cambridge, US · Founded 2012 · Delaware corporation · 1 employees on LinkedIn · 14 known investors
Find your way into Cyteir Therapeutics
Sign up to see every warm intro you have to Cyteir Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cyteir Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.
Founders & leadership
Board
Investors · 14
How we know: Droia Ventures's portfolio page · prnewswire.com · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Lightstone Ventures's portfolio page · prnewswire.com · the VCSheet dataset · Not right? Tell us
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: Shah Family Office's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: prnewswire.com · funding news · Not right? Tell us
Also in the syndicate · 4
Reported raises · per SEC filings
Form D private placements$111.9M disclosed across 4 rounds · 2015–2021
▶$80MraisedFeb 2021 · 22 investors · BiotechnologyRule 506(b)
- TIMOTHY ROMBERGERDirector
- PAUL SECRISTExecutive Officer
- ANDREW GENGOSExecutive Officer
- SUSAN MOLINEAUXDirector
- JOSEPH S. ZAKRZEWSKIDirector
- KAREN HONGDirector
- JANWILLEM NAESENSDirector
- JEAN GEORGEDirector
- RACQUEL BRACKENDirector
- MARKUS RENSCHLERExecutive Officer, Director
- Amount sold
- $80M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedOct 2019 · 6 investors · BiotechnologyRule 506(b)
- JANWILLEM NAESENSDirector
- JEAN GEORGEDirector
- RACQUEL BRACKENDirector
- MARKUS RENSCHLERExecutive Officer, Director
- KAREN HONGDirector
- TIMOTHY ROMBERGERExecutive Officer, Director
- Amount sold
- $20.2M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedMay 2018 · 12 investors · BiotechnologyRule 506(b)
- Bart Van HoolandDirector
- Timothy RombergerExecutive Officer, Director
- Ronald GoldsteinExecutive Officer
- Racquel BrackenDirector
- Markus RenschlerExecutive Officer, Director
- Jean GeorgeDirector
- Offering amount
- $35M
- Amount sold
- $5.8M
- Sales commissions
- $1.4M
- Placement agents
- MTS Securities, LLC
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedNov 2016 · 15 investors · Other Health CareRule 506(b)
- Kevin MillsExecutive Officer, Director
- Barry MillsDirector
- Ronald GoldsteinExecutive Officer
- Donald CorcoranExecutive Officer, Director
- Timothy RombergerDirector
- Markus RenschlerDirector
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Cyteir Therapeutics.
In the news
Frequently asked questions
- What does Cyteir Therapeutics do?
- Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Its lead program is being studied in combination with capecitabine and gemcitabine in a Phase 1/2 clinical trial that includes patients with advanced ovarian cancer.
- Who are Cyteir Therapeutics's investors?
- Cyteir Therapeutics's investors include Droia Ventures, Lightstone Ventures, OUP (Osage University Partners), Shah Family Office, Ally Bridge Group, De Novo Ventures, Janus Henderson Investors, Novo Holdings and 2 more.
- How much funding has Cyteir Therapeutics raised?
- Cyteir Therapeutics has disclosed $111.9M raised across 4 rounds.
- Where is Cyteir Therapeutics headquartered?
- Cyteir Therapeutics is headquartered in Cambridge, US.